IN2015MN00139A - - Google Patents
Download PDFInfo
- Publication number
- IN2015MN00139A IN2015MN00139A IN139MUN2015A IN2015MN00139A IN 2015MN00139 A IN2015MN00139 A IN 2015MN00139A IN 139MUN2015 A IN139MUN2015 A IN 139MUN2015A IN 2015MN00139 A IN2015MN00139 A IN 2015MN00139A
- Authority
- IN
- India
- Prior art keywords
- protein
- fragments
- present
- hetero dimeric
- immunoglobulinvariants
- Prior art date
Links
- 101710120037 Toxin CcdB Proteins 0.000 abstract 3
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 239000012634 fragment Substances 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 229940072221 immunoglobulins Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000000746 purification Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
- B01D15/08—Selective adsorption, e.g. chromatography
- B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
- B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
- B01D15/3804—Affinity chromatography
- B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261705278P | 2012-09-25 | 2012-09-25 | |
| PCT/EP2013/069989 WO2014049003A1 (en) | 2012-09-25 | 2013-09-25 | Purification of hetero-dimeric immunoglobulins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015MN00139A true IN2015MN00139A (cs) | 2015-10-16 |
Family
ID=49237223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN139MUN2015 IN2015MN00139A (cs) | 2012-09-25 | 2013-09-25 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150239991A1 (cs) |
| EP (2) | EP3401337A1 (cs) |
| JP (5) | JP2015529236A (cs) |
| KR (1) | KR20150076172A (cs) |
| CN (1) | CN104968685A (cs) |
| AU (2) | AU2013322710A1 (cs) |
| CA (2) | CA2886036A1 (cs) |
| HK (1) | HK1215950A1 (cs) |
| IL (2) | IL237872B (cs) |
| IN (1) | IN2015MN00139A (cs) |
| WO (1) | WO2014049003A1 (cs) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| MX2011010168A (es) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Anticuerpos biespecificos, trivalentes. |
| US9676845B2 (en) | 2009-06-16 | 2017-06-13 | Hoffmann-La Roche, Inc. | Bispecific antigen binding proteins |
| MX2012003396A (es) | 2009-09-16 | 2012-04-10 | Genentech Inc | Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos. |
| AR080793A1 (es) | 2010-03-26 | 2012-05-09 | Roche Glycart Ag | Anticuerpos biespecificos |
| EP2609111B1 (en) | 2010-08-24 | 2017-11-01 | F. Hoffmann-La Roche AG | Bispecific antibodies comprising a disulfide stabilized-fv fragment |
| MX341921B (es) | 2011-02-28 | 2016-09-07 | Hoffmann La Roche | Proteinas de union a antigeno. |
| JP5768147B2 (ja) | 2011-02-28 | 2015-08-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 一価抗原結合タンパク質 |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| CA2904806C (en) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Human fcrn-binding modified antibodies and methods of use |
| WO2015033223A2 (en) * | 2013-09-03 | 2015-03-12 | Novimmune S.A. | Readily isolated bispecific binding molecules with native format having mutated constant regions |
| WO2015052230A1 (en) | 2013-10-11 | 2015-04-16 | F. Hoffmann-La Roche Ag | Multispecific domain exchanged common variable light chain antibodies |
| SG11201603244VA (en) | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
| CA2932364A1 (en) | 2014-01-15 | 2015-07-23 | F. Hoffmann-La Roche Ag | Fc-region variants with improved protein a-binding |
| PL3122781T3 (pl) | 2014-03-28 | 2020-06-15 | Xencor, Inc. | Dwuswoiste przeciwciała, które wiążą się z CD38 i CD3 |
| AR101262A1 (es) * | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
| CN106573986A (zh) * | 2014-07-29 | 2017-04-19 | 豪夫迈·罗氏有限公司 | 多特异性抗体 |
| US11773166B2 (en) | 2014-11-04 | 2023-10-03 | Ichnos Sciences SA | CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production |
| MA40894A (fr) * | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| TN2017000222A1 (en) | 2014-11-26 | 2018-10-19 | Xencor Inc | Heterodimeric antibodies that bind cd3 and cd38 |
| ES2764111T3 (es) | 2014-12-03 | 2020-06-02 | Hoffmann La Roche | Anticuerpos multiespecíficos |
| WO2017005649A1 (en) | 2015-07-09 | 2017-01-12 | Genmab A/S | Bispecific and multispecific antibodies and method for isolation of such |
| EP3365366B1 (en) | 2015-10-25 | 2021-07-14 | Sanofi | Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection |
| GB201602156D0 (en) * | 2016-02-05 | 2016-03-23 | Jones Philip C And Boku University Of Natural Resources And Life Sciences | Heterodimers and purification thereof |
| TN2020000058A1 (en) | 2016-04-13 | 2022-01-06 | Sanofi Sa | Trispecific and/or trivalent binding proteins |
| EP3443006B1 (en) * | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| MA56474A (fr) * | 2016-05-02 | 2022-05-11 | Hoffmann La Roche | Contorsbody - liant de cible à chaîne unique |
| US11498977B2 (en) * | 2016-09-29 | 2022-11-15 | Beijing Hanmi Pharmaceutical Co., Ltd. | Heterodimeric immunoglobulin constructs and preparation methods thereof |
| CN109963876B (zh) | 2016-11-18 | 2023-11-14 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN110770255B (zh) | 2017-04-11 | 2025-07-01 | 因荷布瑞克斯生物科学公司 | 具有受限cd3结合的多特异性多肽构建体及其使用方法 |
| WO2019153200A1 (zh) | 2018-02-08 | 2019-08-15 | 北京韩美药品有限公司 | 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN119881293A (zh) | 2018-03-21 | 2025-04-25 | 沃特世科技公司 | 基于非抗体高亲和力的样品制备、吸附剂、装置和方法 |
| CN112218686A (zh) | 2018-04-11 | 2021-01-12 | 印希比股份有限公司 | 具有受限cd3结合的多特异性多肽构建体以及相关方法和用途 |
| FR3080621B1 (fr) * | 2018-04-26 | 2022-12-09 | Univ Limoges | Nouvelle classe d'immunoglobuline recombinante de type g : igg5, codee par le pseudo-gene gamma humain de chaine lourde |
| CA3104390A1 (en) | 2018-06-22 | 2019-12-26 | Genmab A/S | Method for producing a controlled mixture of two or more different antibodies |
| US12195533B2 (en) | 2018-07-24 | 2025-01-14 | Inhibrx Biosciences, Inc. | Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same |
| CN120623346A (zh) | 2018-10-11 | 2025-09-12 | 因荷布瑞克斯生物科学公司 | Pd-1单结构域抗体及其治疗组合物 |
| JP2022512684A (ja) | 2018-10-11 | 2022-02-07 | インヒブルクス インコーポレイテッド | Ｂ７ｈ３シングルドメイン抗体およびその治療用組成物 |
| CA3115089A1 (en) | 2018-10-11 | 2020-04-16 | Inhibrx, Inc. | Dll3 single domain antibodies and therapeutic compositions thereof |
| TWI863932B (zh) | 2018-10-11 | 2024-12-01 | 美商因荷布瑞克斯生物科學公司 | 5t4單域抗體及其治療性組合物 |
| WO2020136564A1 (en) | 2018-12-24 | 2020-07-02 | Sanofi | Pseudofab-based multispecific binding proteins |
| US11613576B2 (en) | 2019-04-09 | 2023-03-28 | Sanofi | Trispecific binding proteins, methods, and uses thereof |
| EP4141025A4 (en) * | 2019-12-26 | 2024-04-24 | ABL Bio, Inc. | METHOD FOR PURIFICATION OF BIOLOGICALLY ACTIVE PEPTIDES USING PROTEIN A AFFINITY CHROMATOGRAPHY |
| IL294879A (en) | 2020-01-29 | 2022-09-01 | Inhibrx Inc | Cd28 single domain antibodies and multivalent and multispecific constructs thereof |
| US12037399B2 (en) | 2020-10-07 | 2024-07-16 | Dren Bio, Inc. | Anti-Dectin-1 antibodies and methods of use thereof |
| JP2024527262A (ja) | 2021-06-16 | 2024-07-24 | アレクトル エルエルシー | 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法 |
| WO2022266221A1 (en) | 2021-06-16 | 2022-12-22 | Alector Llc | Monovalent anti-mertk antibodies and methods of use thereof |
| JP2023092810A (ja) * | 2021-12-22 | 2023-07-04 | 国立大学法人東京農工大学 | 変異抗体、変異抗体の製造方法 |
| KR20250035053A (ko) | 2022-06-07 | 2025-03-11 | 리제너론 파아마슈티컬스, 인크. | T 세포 활성을 조절하기 위한 다중특이적 분자 및 이의 용도 |
| EP4561614A1 (en) | 2022-07-29 | 2025-06-04 | Alector LLC | Cd98hc antigen-binding domains and uses therefor |
| KR20250044671A (ko) | 2022-07-29 | 2025-04-01 | 알렉터 엘엘씨 | 트랜스페린 수용체 항원-결합 도메인 및 이의 용도 |
| EP4581059A2 (en) * | 2022-09-02 | 2025-07-09 | Zoetis Services LLC | Equine antibody mutants |
| WO2024102948A1 (en) | 2022-11-11 | 2024-05-16 | Celgene Corporation | Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods |
| US12195546B2 (en) | 2022-12-19 | 2025-01-14 | Sanofi | CD28/OX40 bispecific antibodies |
| WO2025038668A1 (en) | 2023-08-14 | 2025-02-20 | Voro Therapeutics, Inc. | Therapeutic binding agents that conditionally promote myeloid cell activity against target cells and uses thereof |
| WO2025087386A1 (zh) * | 2023-10-25 | 2025-05-01 | 正大天晴药业集团南京顺欣制药有限公司 | 抗her2抗体药物偶联物治疗乳腺癌的用途 |
| WO2025166077A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Compositions comprising progranulin and uses thereof |
| WO2025166040A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Multi-specific binding proteins that bind to gpnmb and a blood brain barrier target and methods of use thereof |
| WO2025166042A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | Cd98hc antigen-binding domains and uses therefor |
| WO2025166045A1 (en) | 2024-01-31 | 2025-08-07 | Alector Llc | β-GLUCOCEREBROSIDASE ENZYMES, FUSION PROTEINS AND COMPLEXES COMPRISING THE SAME, AND METHODS OF USE THEREOF |
| WO2025240670A2 (en) | 2024-05-15 | 2025-11-20 | Abalytics Oncology, Inc. | Anti-pd-1 antibodies and related binding molecules and methods and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0739904A1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| DE69132709T2 (de) | 1990-06-29 | 2002-06-20 | Large Scale Biology Corp., Vacaville | Melaninproduktion durch transformierte mikroorganismen |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE122009000068I2 (de) | 1994-06-03 | 2011-06-16 | Ascenion Gmbh | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| DK0826696T3 (da) | 1996-09-03 | 2002-09-23 | Gsf Forschungszentrum Umwelt | Anvendelse af bi- og trispecifikke antistoffer til inducering af en tumorimmunitet |
| US6322788B1 (en) * | 1998-08-20 | 2001-11-27 | Stanley Arthur Kim | Anti-bacterial antibodies and methods of use |
| US8142780B2 (en) * | 1998-08-20 | 2012-03-27 | Strox Biopharmaceuticals, Llc | Anti-bacterial antibodies |
| EA015148B1 (ru) * | 2005-06-17 | 2011-06-30 | Элан Фарма Интернэшнл Лимитед | СПОСОБЫ ОЧИСТКИ Aβ-СВЯЗЫВАЮЩЕГО БЕЛКА, СОДЕРЖАЩЕГО ОБЛАСТЬ FC |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| EP1999154B1 (en) | 2006-03-24 | 2012-10-24 | Merck Patent GmbH | Engineered heterodimeric protein domains |
| EP2035456A1 (en) | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
| SI2129396T1 (sl) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Protitelesa proti ErbB3 in njihove uporabe |
| DK2235064T3 (en) | 2008-01-07 | 2016-01-11 | Amgen Inc | A process for the preparation of heterodimeric Fc molecules using electrostatic control effects |
| CA2738565C (en) * | 2008-10-01 | 2023-10-10 | Micromet Ag | Cross-species-specific psmaxcd3 bispecific single chain antibody |
| CN102264759B (zh) * | 2008-12-23 | 2016-05-11 | 弗·哈夫曼-拉罗切有限公司 | 与蛋白a的结合改变的免疫球蛋白变体 |
| BRPI1005984A2 (pt) | 2009-02-23 | 2016-10-04 | Glenmark Pharmaceuticals Sa | anticorpo humanizado ou fragmento do mesmo que se liga ao cd19 humano, acido nucleico isolado, vetor, célula hospedeira, método para produzir um anticorpo humanizado ou fragmento do mesmo que se liga à cd12 humano, composição, imunoconjugado, uso de um anticorpo humanizado ou fragmento do mesmo, artigo de manufatura e kit |
| MA33198B1 (fr) | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| MY199658A (en) | 2009-06-26 | 2023-11-14 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| KR101856792B1 (ko) * | 2009-12-25 | 2018-05-11 | 추가이 세이야쿠 가부시키가이샤 | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 |
| BR112012026766B1 (pt) * | 2010-04-20 | 2021-11-03 | Genmab A/S | Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico |
| MX358752B (es) | 2011-03-25 | 2018-08-31 | Glenmark Pharmaceuticals Sa | Inmunoglobulinas heterodiméricas. |
| US9114516B2 (en) | 2011-07-21 | 2015-08-25 | Illinois Tool Works Inc. | Portable combustion gas-powered tools with combustion chamber lockout system |
| ES2739808T3 (es) * | 2011-10-27 | 2020-02-04 | Genmab As | Producción de proteínas heterodiméricas |
| EP2823422A1 (en) | 2012-03-06 | 2015-01-14 | FOSS Analytical AB | Method, software and graphical user interface for forming a prediction model for chemometric analysis |
| JP6273219B2 (ja) | 2012-03-13 | 2018-01-31 | ノビミューン エスアー | 天然の免疫グロブリン形式を有する容易に単離される二重特異性抗体 |
| AU2013322710A1 (en) * | 2012-09-25 | 2015-04-16 | Glenmark Pharmaceuticals S.A. | Purification of hetero-dimeric immunoglobulins |
| SG11201603244VA (en) * | 2013-11-04 | 2016-05-30 | Glenmark Pharmaceuticals Sa | Production of t cell retargeting hetero-dimeric immunoglobulins |
-
2013
- 2013-09-25 AU AU2013322710A patent/AU2013322710A1/en not_active Abandoned
- 2013-09-25 CA CA2886036A patent/CA2886036A1/en not_active Abandoned
- 2013-09-25 US US14/431,207 patent/US20150239991A1/en not_active Abandoned
- 2013-09-25 JP JP2015532465A patent/JP2015529236A/ja active Pending
- 2013-09-25 CN CN201380061419.1A patent/CN104968685A/zh active Pending
- 2013-09-25 IN IN139MUN2015 patent/IN2015MN00139A/en unknown
- 2013-09-25 KR KR1020157010732A patent/KR20150076172A/ko not_active Ceased
- 2013-09-25 WO PCT/EP2013/069989 patent/WO2014049003A1/en not_active Ceased
- 2013-09-25 EP EP18177798.8A patent/EP3401337A1/en not_active Withdrawn
- 2013-09-25 CA CA3061557A patent/CA3061557A1/en active Pending
- 2013-09-25 HK HK16103843.5A patent/HK1215950A1/zh unknown
- 2013-09-25 EP EP13766540.2A patent/EP2900696A1/en not_active Ceased
-
2015
- 2015-03-22 IL IL237872A patent/IL237872B/en active IP Right Grant
-
2018
- 2018-02-07 JP JP2018020450A patent/JP2018104444A/ja active Pending
- 2018-06-15 AU AU2018204314A patent/AU2018204314B2/en active Active
- 2018-11-30 JP JP2018224809A patent/JP6856610B2/ja not_active Expired - Fee Related
-
2019
- 2019-02-14 US US16/275,821 patent/US20200010568A1/en not_active Abandoned
- 2019-09-09 IL IL269207A patent/IL269207B/en unknown
-
2020
- 2020-03-04 JP JP2020036853A patent/JP2020105203A/ja not_active Ceased
-
2022
- 2022-06-07 JP JP2022092045A patent/JP2022116326A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20150239991A1 (en) | 2015-08-27 |
| WO2014049003A1 (en) | 2014-04-03 |
| IL269207A (en) | 2019-11-28 |
| AU2013322710A1 (en) | 2015-04-16 |
| HK1215950A1 (zh) | 2016-09-30 |
| JP2019073512A (ja) | 2019-05-16 |
| EP2900696A1 (en) | 2015-08-05 |
| CA3061557A1 (en) | 2014-04-03 |
| JP2020105203A (ja) | 2020-07-09 |
| JP2022116326A (ja) | 2022-08-09 |
| JP2015529236A (ja) | 2015-10-05 |
| AU2013322710A2 (en) | 2015-05-07 |
| IL237872B (en) | 2019-09-26 |
| US20200010568A1 (en) | 2020-01-09 |
| AU2018204314A1 (en) | 2018-07-05 |
| CA2886036A1 (en) | 2014-04-03 |
| IL269207B (en) | 2022-02-01 |
| IL237872A0 (en) | 2015-05-31 |
| JP2018104444A (ja) | 2018-07-05 |
| AU2018204314B2 (en) | 2020-05-14 |
| JP6856610B2 (ja) | 2021-04-07 |
| CN104968685A (zh) | 2015-10-07 |
| KR20150076172A (ko) | 2015-07-06 |
| EP3401337A1 (en) | 2018-11-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015MN00139A (cs) | ||
| IL282226A (en) | ST2 antigen-binding proteins | |
| WO2013138793A3 (en) | Affinity reagants for protein purification | |
| PH12014501108A1 (en) | Anti-il-36r antibodies | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| IL254652B (en) | Unnatural albumin binding sites | |
| EA201791693A1 (ru) | Гетеродимерные иммуноглобулины | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| TN2015000124A1 (en) | Compositions and methods for antibodies targeting epo | |
| GB201012599D0 (en) | Process for purifying proteins | |
| EP3067367A4 (en) | Method for purifying recombinant protein | |
| SG2014010334A (en) | Fn14 binding proteins and uses thereof | |
| PH12015500752A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 | |
| IL229722A0 (en) | Dimeric binding proteins based on modified ubiquitin | |
| MX2014001766A (es) | Anticuerpos de neuregulina y sus usos. | |
| WO2013093627A3 (en) | In silico affinity maturation | |
| MX2015004892A (es) | Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21. | |
| WO2013160291A3 (en) | Archease as rna ligase complex member | |
| TN2014000207A1 (en) | Anti il-36r antibodies | |
| TN2013000186A1 (en) | Anti-il-23 antibodies |